Indol-3-yl-carbonyl-spiro-piperidine derivatives

A pharmaceutical composition comprising a compound of formula (I)

• wherein
• A is selected from the following groups (a), (b), (c), (d), (e) and (f):
• each X is the same or different and is CRiiiRiv, NRiii or O, wherein in (a), only one X can be O, the other being CRiiiRiv or NRiii;
• R1 is H,
• C1-6-alkyl optionally substituted by CN,
• aryl, 5 or 6 membered heteroaryl or sulfonylaryl each of which is optionally substituted by one or more B,
• —(CH2)m—Ra wherein Ra is:
• ORi,
• NRiRii, or
• C3-6-cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more B,
• or —(CH2)n—(CO)—Rb or —(CH2)n-(SO2)—Rb, wherein R is:
• C1-6-alkyl,
• C1-6-alkoxy,
• C3-6-cycloalkyl,
• —(CH2)m—NRiiiRiv,
• NRiRii, or
• C3-6-cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more B,
• or R1 and R3 together with the indole ring to which they are attached form a 5 or 6 membered heterocycloalkyl which can be substituted by (CO);
• there can be one or more R2 wherein each
• R2 is H, OH, halo, CN, nitro, C1-6-alkyl optionally substituted by —NRiiiRiv, C1-6-alkoxy, —O—CH2—C2-6-alkenyl, benzyloxy, or C1-6-haloalkyl,
• or two R2 together with the indole ring to which they are attached form an oxo or dioxo bridge;
• R3 is H,
• halo,
• —(CO)—Rc, wherein Rc is:
• C1-6-alkyl,
• —(CH2)n—NRiRii,
• —(CH2)n—NRiiiRiv, or
• 5 or 6 membered heterocycloalkyl optionally substituted by C1-6-alkyl,
• or C1-6-alkyl or aryl, each of which is optionally substituted by halo,
• —O(CO)—C1-6-alkyl,
• or —NH(CO)Rd, wherein Rd is C1-6-alkyl optionally substituted by halo or nitro, or Rd is aryl or a 5 or 6 membered heteroaryl, each of which is optionally substituted by halo, nitro, C1-6-alkyl or C1-6-haloalkyl;
• there can be one or more R4 wherein each
• R4 H, halo, C1-6 alkyl, C1-6 alkoxy, or CN,
• or two R4 together with the phenyl ring to which they are attached form an oxo or dioxo bridge;
• B is halo,
• CN,
• NRiRii,
• C1-6-alkyl optionally substituted by CN, halo or C1-6-alkoxy,
• C1-6-alkoxy,
• C1-6-haloalkoxy,
• C3-6-cycloalkyl,
• —C(O)O—C1-6-alkyl,
• —C(O) NRiRii,
• —C(O)—C1-6-alkyl,
• —S(O)2—C1-6-alkyl,
• —S(O)2—NRiRii, or
• (CRiiiRiv)n-phenyl, or (CRiiiRiv)n-5 or 6 membered heteroaryl wherein the phenyl or 5 or 6 membered heteroaryl moiety is optionally substituted by one or more substituent(s) selected from the group consisting of:
• halo, CN, NRiRii, C1-6-alkyl optionally substituted by CN or C1-6-alkoxy, C1-6-alkoxy, C1-6-haloalkoxy, C3-6-cycloalkyl, —C(O)O—C1-6-alkyl, —C(O)—NRiRii, —C(O)—C1-6-alkyl, —S(O)2—C1-6-alkyl, and —S(O)2—NRiRii;
• Ri and Rii are each independently H, C1-6-alkyl, C1-6-alkylene-NRiiiRiv, —(CO)O—C1-6-alkyl, —C(O)—NRiiiRiv, —C(O)—C1-6-alkyl, —S(O)2—C1-6-alkyl or —S(O)2—NRiiiRiv;
• Riii is H, C1-6-alkyl or C1-6-alkylene—N(Riv)2;
• Riv is H or C1-6-alkyl;
• m is 1 to 6;
• and
• n is 0 to 4;
• or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.